Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Hum Vaccin Immunother ; 17(12): 5603-5613, 2021 12 02.
Artigo em Inglês | MEDLINE | ID: mdl-34890520

RESUMO

Invasive meningococcal disease (IMD) is an uncommon yet unpredictable, severe, and life-threatening disease with the highest burden in young children. In Chile, most IMD is caused by meningococcal serogroup B (MenB) and W (MenW) infection. In response to a MenW outbreak in 2012, a toddler vaccination program was implemented using quadrivalent meningococcal conjugate vaccine against serogroups A, C, W and Y (MenACWY). The vaccine program, however, does not protect infants or other unvaccinated age groups and does not protect against MenB IMD. Since 2017, MenB IMD cases are becoming increasingly prevalent. Using a dynamic transmission model adapted for Chile, this analysis assessed the public health impact (reduction in IMD cases, long-term sequelae, deaths, and quality-adjusted life-years) of six alternative vaccination strategies using MenACWY and/or the four-component MenB (4CMenB) vaccine in infants, toddlers, and/or adolescents compared to the National Immunization Program (NIP) implemented in 2014. Strategies that added infant 4CMenB to MenACWY in toddlers or adolescents would prevent more IMD than the current NIP, observed within the first 5 years of the program. Replacing the NIP by an adolescent MenACWY strategy would prevent more IMD in the longer term, once herd immunity is established to protect unvaccinated infants or older age groups. The strategy that maximized reduction of IMD cases and associated sequelae in all age groups with immediate plus long-term benefits included infant 4CMenB and MenACWY in both toddlers and adolescents. This analysis can help policymakers determine the best strategy to control IMD in Chile and improve public health. A set of audio slides linked to this manuscript can be found at https://doi.org/10.6084/m9.figshare.16837543.


Plain Language Summary (PLS)What is the context?Invasive meningococcal disease (IMD) is a severe, sometimes fatal, unpredictable disease with highest rates in infants, young children, and adolescents. It is caused by different serogroups of Neisseria meningitidis bacteria. Most cases in Chile are due to meningococcal serogroups B (MenB) and W (MenW). Following a MenW IMD outbreak in 2012, vaccination was introduced, leading to the current National Immunization Program (NIP) in toddlers with quadrivalent meningococcal conjugate vaccine (MenACWY) (protecting against IMD caused by MenA, C, W, and Y).What is new?A disease model to predict the impact of vaccination strategies in the Chilean population compared six alternative strategies, using the multi-component MenB (4CMenB) vaccine for infants (protecting against MenB, with potential cross-protection against MenW and Y IMD) and/or the MenACWY vaccine for toddlers and/or adolescents.What is the impact?Results, compared to the NIP, show that: Strategy 1 (a program targeting only infants with 4CMenB) would reduce more MenB cases but fewer MenA, C, W and Y cases resulting in a lower reduction of total IMD cases in the long term; Strategy 3 (a program targeting only adolescents with MenACWY) would have a similar effect to the NIP in the short term but a far greater IMD reduction in the long term (as vaccinating this age group eventually reduces transmission to other age groups, reducing their risk of disease); all the other strategies targeted more than one age group, further reducing numbers of IMD cases compared with the NIP. The greatest benefits were seen with infant 4CMenB vaccination combined with toddler and adolescent MenACWY vaccination. Results can help policymakers determine the best IMD strategy to maximize the benefits of available meningococcal vaccines.


Assuntos
Infecções Meningocócicas , Vacinas Meningocócicas , Adolescente , Idoso , Pré-Escolar , Chile/epidemiologia , Progressão da Doença , Humanos , Programas de Imunização , Lactente , Infecções Meningocócicas/epidemiologia , Infecções Meningocócicas/prevenção & controle , Saúde Pública , Vacinação , Vacinas Conjugadas
2.
J Dual Diagn ; 17(4): 277-283, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34392807

RESUMO

OBJECTIVE: Prepulse inhibition regulates sensorimotor gating and is a marker of vulnerability to certain disorders. We compared prepulse inhibition, psychopathy, and sensitivity to punishment and reward in patients with cocaine-related disorder without psychiatric comorbidities and a control group. METHODS: This was an observational study of a sample of 22 male cases with cocaine-related disorder and 22 healthy male controls. We used the Psychiatric Research Interview for Substance and Mental Disorders and Mini International Neuropsychiatric Interview; the Sensitivity to Punishment and Sensitivity to Reward Questionnaire; and the Levenson Self-Report Psychopathy Scale and Hare Psychopathy Checklist-Revised. Prepulse inhibition was evaluated at 30, 60, and 120 ms. RESULTS: Cocaine-related disorder group had a higher overall score (t = 12.556, p = .001) and primary psychopathy score (t = 3.750, p = .001) on Levenson Self-Report Psychopathy Scale, a higher score on both Hare Psychopathy Checklist-Revised factors, sensitivity to rewards (t = 3.076, p = .005) and prepulse inhibition at 30 ms (t = 2.859, p = .008). CONCLUSIONS: Cocaine use in patients without psychiatric comorbidities seems to increase sensorimotor gating. Therefore, these patients likely have an increased sensitivity to rewards, causing them to focus more on cocaine-boosting stimuli, thus explaining the psychopathic traits of these individuals.


Assuntos
Transtornos Relacionados ao Uso de Cocaína , Cocaína , Transtorno da Personalidade Antissocial/epidemiologia , Cocaína/efeitos adversos , Transtornos Relacionados ao Uso de Cocaína/complicações , Transtornos Relacionados ao Uso de Cocaína/epidemiologia , Humanos , Masculino , Escalas de Graduação Psiquiátrica , Filtro Sensorial
3.
Am J Emerg Med ; 38(11): 2395-2399, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-33039225

RESUMO

OBJECTIVE: Introducing a new, simple and inexpensive portable equipment for lifeguards, consisting of a pre-assembled full-size plastic blanket with a mask and HEPA filter, which could offer significant time-saving advantages to reduce COVID-19 risk transmission in the first few minutes of CPR after water rescue, avoiding the negative impact of delayed ventilation. METHOD: A pilot study was carried out to determine the feasibility of the pre-assembled kit of face-mask and HEPA filter adapted on a pre-set plastic-blanket. The first step consisted of washing hands, putting on safety glasses and gloves as the first personal protection equipment (PPE) and then covering the victim with an assembled plastic blanket. The second step consisted of 10 min of cardiopulmonary resuscitation (CPR) with PPE and plastic blanket, following the technical recommendations for ventilation during COVID-19. RESULTS: Ten rescuers took part in the pilot study. The average time to wear PPE and place the pre-assembly kit on the victim was 82 s [IC 58-105]. After 10 min the quality of the resuscitation (QCPR) was 91% [87-94]. Quality chest compressions (CC) were 22% better than ventilations (V). Most of the rescuers (60%) thought that placing the plastic blanket on the victim on the beach was somewhat simple or very simple. CONCLUSIONS: Resuscitation techniques in COVID-19 era at the beach have added complexities for the correct use of PPE. Plastic blanket plus basic ventilations equipment resource could be a new alternative to be considered for lifeguards to keep ventilation on use while reducing risk transmission.


Assuntos
Reanimação Cardiopulmonar/instrumentação , Máscaras , Afogamento Iminente/terapia , Equipamento de Proteção Individual , Filtros de Ar , Praias , COVID-19 , Reanimação Cardiopulmonar/métodos , Afogamento , Socorristas , Humanos , Manequins , Projetos Piloto , Plásticos
4.
Rev. esp. quimioter ; 32(3): 208-216, jun. 2019. ilus, tab
Artigo em Espanhol | IBECS | ID: ibc-188513

RESUMO

La enfermedad meningocócica invasiva (EMI), causada por la bacteria Neisseria meningitidis, supone una mortalidad y morbilidad significativas. La incidencia de la enfermedad alcanza el máximo entre lactantes <1 año y niños pequeños en todo el mundo. En Europa, el serogrupo B de N. meningitidis es responsable de más del 50 % de todos los casos de EMI, mientras que en Latinoamérica la mayoría de los casos de EMI se deben a los serogrupos B o C. El desarrollo de una vacuna efectiva frente al serogrupo B ha supuesto un reto para los investigadores a lo largo de más de medio siglo. Los polisacáridos capsulares del serogrupo B no eran antígenos vacunales apropiados, y el éxito de las vacunas de vesículas de la membrana externa (OMV) se limitaba a las cepas bacterianas homólogas. La vacunología inversa permitió desarrollar una vacuna meningocócica de 4 componentes que incluía tres antígenos novedosos y las OMVs (4CMenB). Cada componente de la vacuna posee una diana distinta. La vacuna 4CMenB ha sido autorizada basándose en datos de inmunogenicidad y seguridad, debido a que la baja incidencia de la enfermedad impide la realización de estudios de eficacia clínica. El análisis de anticuerpos bactericidas en suero con complemento humano (hSBA) mide los anticuerpos funcionales del suero de los sujetos vacunados (es decir, la inmunogenicidad vacunal) y constituye un correlato de protección aceptado. La cobertura de cepas vacunales se ha evaluado tanto mediante el análisis de la hSBA, como mediante otro método más conservador denominado Sistema de Tipificación de Antígenos Meningocócicos (MATS). Desde 2013, se han recogido datos de efectividad en vida real de 4CMenB. La vacuna resultó efectiva en el control de brotes de Norteamérica y los datos recientes de introducción de la vacuna en el programa nacional de vacunación de lactantes del Reino Unido, han revelado una efectividad vacunal del 82,9 % tras las dos primeras dosis, junto a un perfil de seguridad aceptable


Invasive meningococcal disease (IMD), caused by the bacterium Neisseria meningitidis, entails significant mortality and morbidity. Disease incidence is highest in infants <1 year and young children globally. In Europe, N. meningitidis serogroup B is responsible for over 50% of overall IMD cases, whereas the majority of IMD cases in Latin America is caused either by serogroup B or C. The development of an effective vaccine against serogroup B has challenged the researchers for over half a century. Serogroup B capsular polysaccharide was an inappropriate vaccine antigen, and the success of outer membrane vesicle (OMV) vaccines was restricted to homologous bacterial strains. Reverse vaccinology led to the development of a 4-component meningococcal vaccine including three novel antigens, and OMVs (4CMenB). Each vaccine component has a different target.4CMenB has been authorised based on its immunogenicity and safety data because the low disease incidence precluded formal clinical efficacy studies. Human serum bactericidal antibody (hSBA) assay tests functional antibodies in the serum of vaccinated individuals (i. e. the vaccine immunogenicity), and is the accepted correlate of protection. Vaccine strain coverage has been assessed both through hSBA assays and a more conservative method named Meningococcal Antigen Typing System (MATS). Effectiveness data of 4CMenB have been collected in the field since 2013. The vaccine proved effective in outbreak control in North America, and recent data from the introduction of the vaccine in the United Kingdom infant national immunisation programme reveal a vaccine effectiveness of 82.9% for the first two doses, with an acceptable safety profile


Assuntos
Humanos , Genoma Bacteriano/genética , Vacinas Meningocócicas/administração & dosagem , Neisseria meningitidis Sorogrupo B/genética , Neisseria meningitidis Sorogrupo B/imunologia , Meningite Meningocócica/imunologia , Meningite Meningocócica/prevenção & controle , Infecções Meningocócicas/prevenção & controle
5.
Hum Vaccin Immunother ; 11(6): 1507-17, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25969894

RESUMO

This phase 2 study assessed the immunogenicity, safety, and reactogenicity of investigational formulations of meningococcal ABCWY vaccines, consisting of recombinant proteins (rMenB) and outer membrane vesicle (OMV) components of a licensed serogroup B vaccine, combined with components of a licensed quadrivalent meningococcal glycoconjugate vaccine (MenACWY-CRM). A total of 495 healthy adolescents were randomized to 6 groups to receive 2 doses (Months 0, 2) of one of 4 formulations of rMenB antigens, with or without OMV, combined with MenACWY-CRM, or 2 doses of rMenB alone or one dose of MenACWY-CRM then a placebo. Immunogenicity was assessed by serum bactericidal assay with human complement (hSBA) against serogroups ACWY and serogroup B test strains; solicited reactions and any adverse events (AEs) were assessed. Two MenABCWY vaccinations elicited robust ACWY immune responses, with higher seroresponse rates than one dose of MenACWY-CRM. Bactericidal antibody responses against the rMenB antigens and OMV components were highest in subjects who received 2 doses of OMV-containing MenABCWY formulations, with ≥68% of subjects achieving hSBA titers ≥5 against each of the serogroup B test strains. After the first dose, solicited local reaction rates were higher in the MenABCWY or rMenB groups than the MenACWY-CRM group, but similar across groups after the second dose, consisting mainly of transient injection site pain. Fever (≥38.0°C) was rare and there were no vaccine-related serious AEs. In conclusion, investigational MenABCWY formulations containing OMV components elicited highly immunogenic responses against meningococcal serogroups ACWY, as well as serogroup B test strains, with an acceptable safety profile. [NCT01210885].


Assuntos
Drogas em Investigação/efeitos adversos , Vacinas Meningocócicas/efeitos adversos , Vacinas Meningocócicas/imunologia , Adolescente , Atividade Bactericida do Sangue , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia , Drogas em Investigação/administração & dosagem , Feminino , Voluntários Saudáveis , Humanos , Masculino , Vacinas Meningocócicas/administração & dosagem , Placebos/administração & dosagem , Vacinas Combinadas/administração & dosagem , Vacinas Combinadas/efeitos adversos , Vacinas Combinadas/imunologia
7.
J Card Fail ; 15(10): 920-8, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19944370

RESUMO

BACKGROUND: Sustained left ventricular (LV) dyssynchrony can lead to heart failure (HF) in the absence of coronary artery stenosis. We tested whether myocardial hibernation underlies the LV functional impairment caused by high-frequency pacing, an established model of nonischemic dilated cardiomyopathy. METHODS AND RESULTS: Regional LV contractile and perfusion reserve were assessed by magnetic resonance imaging, respectively, as end-systolic wall thickening (LVESWT) and myocardial perfusion reserve index (MPRI) at rest and during low-dose dobutamine stress (LDDS, 10 microg.kg.min intravenously for 10minutes) in failing minipigs (n=8). LV tissue was analyzed for glycogen deposits and other molecular hallmarks of hibernation. LDDS caused a marked increase in LVESWT (27+/-2.98 vs. 7.15+/-3 %, P < .05) and MPRI (2.1+/-0.5 vs. 1.3+/-0.3 P < .05) in the region that was activated first (pacing site) compared with the opposite region. Myocardial glycogen content was markedly increased in the pacing site (P < .05 vs. opposite region). In addition, gene expression of glycogen phosphorylase was reduced in pacing site compared with opposite regions (0.71+/-0.1 vs. 1.03+/-0.3, P < .05), whereas that of hexokinase type II was globally reduced by 83%. CONCLUSIONS: The combination of high heart rate and sustained dyssynchronous LV contraction causes asymmetrical myocardial hibernation, in absence of coronary artery stenosis.


Assuntos
Modelos Animais de Doenças , Insuficiência Cardíaca/fisiopatologia , Hibernação/fisiologia , Disfunção Ventricular Esquerda/fisiopatologia , Animais , Fenômenos Biomecânicos/fisiologia , Insuficiência Cardíaca/complicações , Masculino , Índice de Gravidade de Doença , Suínos , Porco Miniatura , Disfunção Ventricular Esquerda/complicações
8.
J Appl Physiol (1985) ; 98(3): 1083-90, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15501928

RESUMO

Cellular and isolated vessel experiments have shown that pulsatile and laminar shear stress to the endothelium produces significant release of mediators into the circulation. Periodic acceleration (pG(z)) applied to the whole body in the direction of the spinal axis adds pulses to the circulation, thereby increasing pulsatile and shear stress to the endothelium that should also cause release of mediators into the circulation. The purpose of this study was to determine whether addition of pulses to the circulation through pG(z) would be sufficient to increase shear stress in whole animals and to acutely release mediators and how such a physical maneuver might affect coagulation factors. Randomized control experiments were performed on anesthetized, supine piglets. The treatment group (pG(z)) (n = 12) received pG(z) with a motion platform that moved them repetitively head to foot at +/-0.4 g at 180 cpm for 60 min. The control group (n = 6) was secured to the platform but remained on conventional ventilation throughout the 4-h protocol. Compared with control animals and baseline, pulsatile stress produced significant increases of serum nitrite, prostacyclin, PGE(2), and tissue plasminogen activator antigen and activity, as well as D-dimer. There were no significant changes in epinephrine, norepinephrine, cortisol, and coagulation factors between groups or from baseline values. Pulsatile and laminar shear stress to the endothelium induced by pG(z) safely produces increases of vasoactive and fibrinolytic activity. pG(z) has potential to achieve mediator-related benefits from the actions of nitric oxide and prostaglandins.


Assuntos
Aceleração , Fatores de Coagulação Sanguínea/análise , Fibrinolíticos/sangue , Movimento/fisiologia , Estimulação Física/métodos , Vasodilatadores/sangue , Animais , Periodicidade , Resistência ao Cisalhamento , Estresse Mecânico , Suínos
9.
Endocrine ; 17(3): 169-74, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12108516

RESUMO

Leptin is an adipose tissue-secreted hormone that actively participates in the regulation of energy homeostasis. Besides this principal role, leptin has been implicated in a large variety of neuroendocrine, paracrine, and autocrine actions involved in the regulation of reproductive function in both experimental animals and humans. Although the participation of leptin in female reproduction is well established, any role in male reproductive function is at best tenuous. The aim of this study was to ascertain whether true leptin is present in human seminal fluid and the tissue of its production. Pooled human seminal plasma obtained from healthy donors showed by direct radioimmunoassay (RIA) the presence of radioimmunoassayable leptin. Serial dilutions of unextracted semen paralleled the RIA standard curve, also devoid of interference in the assay. To prove that this activity was true leptin, seminal plasma was subjected to size-exclusion chromatography, which showed that leptin immunoreactivity eluted with the same partition coefficient as cold leptin, 125I-leptin, and 125I-leptin preincubated with seminal plasma. The results demonstrate that true leptin was present in semen in a free form, i.e., without binding proteins. The presence of leptin charge variants in seminal plasma was assessed by anion-exchange chromatography, which showed two peaks of leptin inmunoreactivity, while 125I-leptin eluted as a single peak. Preincubation of 125I-leptin with seminal fluid converted the single peak into a double peak, indicating that components of the seminal fluid introduce a charge variation in leptin. Leptin levels in seminal plasma of 40 healthy men were 0.95+/-0.19 ng/mL while in 5 vasectomized men the levels were 0.92+/-0.25 ng/mL, suggesting that testicular tissues were not the source of seminal leptin. No correlation was observed between leptin concentrations in semen and the physical characteristics of semen samples or physical characteristics of spermatozoids, such as concentration, motility, vitality, or morphology. In conclusion it was unambiguously demonstrated that human leptin is present in seminal fluid, with at least two charge variants and no binding proteins, the most likely source being either seminal vesicles or prostate tissue. The role of seminal fluid leptin in the male reproductive function or sperm capacitation is at present unknown.


Assuntos
Leptina/metabolismo , Sêmen/metabolismo , Adulto , Índice de Massa Corporal , Cromatografia em Gel , Cromatografia por Troca Iônica , Humanos , Leptina/biossíntese , Masculino , Pessoa de Meia-Idade , Radioimunoensaio , Sêmen/química , Contagem de Espermatozoides , Motilidade dos Espermatozoides/fisiologia , Testículo/metabolismo , Vasectomia
10.
Acta physiol. pharmacol. latinoam ; 38(1): 69-75, ene.-mar. 1988. ilus
Artigo em Inglês | LILACS | ID: lil-96490

RESUMO

Se investigaron los efectos de nitroprusiato de sodio sobre la actividad contráctil isométrica (TCI) y sobre la contractura inducida por ClK 60 mM en vena porta aislada de rata e incubada en condiciones en que se modifican el influjo y eflujo de calcio. En condiciones control (medio (KRB) la TCI fue de 10.61ñ0.56mN(n=13). La adición de concentraciones crecientes de NPS (no acumulativas) disminuyó la TCI de manera dosis dependente directa. El componente tónico de la contractura inducida por ClK 60 mM decayó en un 27.04ñ10.9% (n=6) depués del agregado de NPS 10-4M. El efecto relajante de la droga fue más pronunciado en presencia de nifedipina 10-10M (72.35ñ7.5% de inhibición). La sensibilidad de la preparación a NPS se redujo fuertemente en condiciones en que el eflujo de Ca+2 estaba disminuido (medio pobre en sodio = KRB sucrosa). Los experimentos aquí presentados apoyan la hipótesis de que el efecto vasodilatador de NPS podría ser atribuido a un incrementado eflujo del catión


Assuntos
Ratos , Animais , Masculino , Contração Muscular , Ferricianetos/farmacologia , Técnicas In Vitro , Músculo Liso Vascular , Nitroprussiato/farmacologia , Potássio/farmacologia , Músculo Liso Vascular/fisiologia , Veia Porta/efeitos dos fármacos , Veia Porta/fisiologia
11.
Acta physiol. pharmacol. latinoam ; 38(1): 69-75, ene.-mar. 1988. ilus
Artigo em Inglês | BINACIS | ID: bin-27281

RESUMO

Se investigaron los efectos de nitroprusiato de sodio sobre la actividad contráctil isométrica (TCI) y sobre la contractura inducida por ClK 60 mM en vena porta aislada de rata e incubada en condiciones en que se modifican el influjo y eflujo de calcio. En condiciones control (medio (KRB) la TCI fue de 10.61ñ0.56mN(n=13). La adición de concentraciones crecientes de NPS (no acumulativas) disminuyó la TCI de manera dosis dependente directa. El componente tónico de la contractura inducida por ClK 60 mM decayó en un 27.04ñ10.9% (n=6) depués del agregado de NPS 10-4M. El efecto relajante de la droga fue más pronunciado en presencia de nifedipina 10-10M (72.35ñ7.5% de inhibición). La sensibilidad de la preparación a NPS se redujo fuertemente en condiciones en que el eflujo de Ca+2 estaba disminuido (medio pobre en sodio = KRB sucrosa). Los experimentos aquí presentados apoyan la hipótesis de que el efecto vasodilatador de NPS podría ser atribuido a un incrementado eflujo del catión (AU)


Assuntos
Ratos , Animais , Masculino , Técnicas In Vitro , Ferricianetos/farmacologia , Contração Muscular/efeitos dos fármacos , Músculo Liso Vascular/efeitos dos fármacos , Nitroprussiato/farmacologia , Potássio/farmacologia , Músculo Liso Vascular/fisiologia , Veia Porta/efeitos dos fármacos , Veia Porta/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA